SOURCE: OctoPlus

April 27, 2007 01:59 ET

OctoPlus Announces Analyst Meeting on May 1

LEIDEN, NETHERLANDS -- (MARKET WIRE) -- April 27, 2007 -- OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery and development company, announces today that it will host an analyst meeting on May 1. The Company invites analysts to attend the meeting in Leiden at 2:30 PM CET on Tuesday, May 1, 2007.

OctoPlus' senior management will present a comprehensive overview of the Company's strategy, product development and clinical development status.

Analysts who would like to attend the meeting should confirm their attendance via email to IR@octoplus.nl.

Presentations from this meeting will be available from OctoPlus' website on May 2nd.

About OctoPlus

OctoPlus N.V. is a product-oriented biopharmaceutical company committed to the development of improved pharmaceutical products that are based on its proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. Rather than seeking to discover novel drug candidates through early stage research activities, OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics and other drugs.

OctoPlus is also a leading provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industry, with a focus on difficult to formulate active pharmaceutical ingredients in injectable formulations. The earnings and expertise that OctoPlus derives from rendering formulation and manufacturing services help to support its own drug development programs.

OctoPlus is listed on Euronext Amsterdam under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl.

This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus N.V. and the industry in which it operates. These statements are based on OctoPlus N.V.'s current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.

Press release in PDF:

http://hugin.info/137076/R/1122554/207119.pdf

Contact Information

  • For further information, please contact:
    Rianne Roukema
    Corporate Communications:
    +31 (71) 524 4044